AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Poxel Announces Participation at the Oppenheimer 29th Annual Healthcare Conference

March 18, 2019

LYON, France--(BUSINESS WIRE)--Mar 18, 2019--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the Oppenheimer 29 th Annual Healthcare Conference.

The Oppenheimer 29 th Healthcare Conference is being held on March 19-20, 2019 at The Westin New York Grand Central Hotel in New York City. The Company will present a corporate overview on Tuesday, March 19 th from 3:55-4:25 PM EDT in the Consulate Room and will be available to participate in one-on-one meetings with investors. The presentation at the Oppenheimer Healthcare Conference will be webcast live. To access the webcast, please visit the following link https://www.veracast.com/webcasts/opco/healthcare2019/51116244164.cfm. The webcast replay will remain available for 90 days following the live presentation.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 T rials of IM eglimin for E fficacy and S afety (TIMES) program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL,  www.poxelpharma.com )

View source version on businesswire.com:https://www.businesswire.com/news/home/20190318005062/en/

CONTACT: Poxel SA

Jonae R. Barnes

Senior Vice President, Investor Relations and Public Relations

jonae.barnes@poxelpharma.com

+1 617 818 2985Investor relations / Media - EU/US

Trophic Communications

Gretchen Schweitzer or Stephanie May

may@trophic.eu

+49 89 238 877 34 or +49 171 185 56 82Investor relations / Media - France

NewCap

Alexia Faure/Nicolas Merigeau

poxel@newcap.eu

+33 1 44 71 98 51

KEYWORD: UNITED STATES EUROPE NORTH AMERICA FRANCE MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL DIABETES

SOURCE: Poxel SA

Copyright Business Wire 2019.

PUB: 03/18/2019 03:00 AM/DISC: 03/18/2019 03:01 AM

http://www.businesswire.com/news/home/20190318005062/en